Pimavanserin is an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It is available as capsules and tablets for oral use. MedsAcross supplies Pimavanserin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
NUPLAZID ® is indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. NUPLAZID is an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.
Source: US FDA prescribing information
The mechanism of action of pimavanserin in the treatment of hallucinations and delusions associated with PDP is unclear. However, the effect of pimavanserin could be mediated through a combination of inverse agonist and antagonist activity at serotonin 5-HT 2A receptors and to a lesser extent at serotonin 5-HT 2C receptors.
Source: US FDA prescribing information
Recommended dose is 34 mg taken orally once daily, without titration. Can be taken with or without food. Capsules may be swallowed whole or opened and entire contents sprinkled over a tablespoon of certain types of soft food.
Source: US FDA prescribing information
NUPLAZID is contraindicated in patients with a history of a hypersensitivity reaction to pimavanserin or any of its components. Rash, urticaria, and reactions consistent with angioedema (e.g., tongue swelling, circumoral edema, throat tightness, and dyspnea) have been reported. Known hypersensitivity to NUPLAZID or any of its components.
Source: US FDA prescribing information
Boxed warning (increased mortality in elderly patients with dementia-related psychosis): Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. NUPLAZID is not approved for the treatment of patients with dementia who experience psychosis unless their hallucinations and delusions are related to Parkinson's disease. QT Interval Prolongation: Increases in QT interval, avoid use with drugs that also increase the QT interval and in patients with risk factors for prolonged QT interval.
Source: US FDA prescribing information
The following serious adverse reactions are discussed elsewhere in the labeling: Increased Mortality in Elderly Patients with Dementia-Related Psychosis QT Interval Prolongation Most common adverse reactions (≥5% and twice the rate of placebo): peripheral edema and confusional state.
Source: US FDA prescribing information
Strong CYP3A4 Inhibitors: Reduce NUPLAZID dose to 10 mg once daily. Strong or Moderate CYP3A4 Inducers: Avoid concomitant use of NUPLAZID.
Source: US FDA prescribing information
Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (59°F and 86°F). To prevent potential capsule color fading, protect from light. 10 mg Tablet: Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (59°F and 86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
3 presentations of Pimavanserin, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Nuplazid 10 mg tabletOral | Acadia Pharmaceuticals | US FDA | Available on request |
| Nuplazid 34 mg capsuleOral | Acadia Pharmaceuticals | US FDA | Available on request |
| Pimavanserin 34 mg capsuleOralGeneric name | — | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 29 April 2016 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Pimavanserin in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 3 presentations of Pimavanserin and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Pimavanserin, including Nuplazid.
Yes. The US FDA first approved Pimavanserin on 29 April 2016, according to Drugs@FDA.
No listed presentation of Pimavanserin is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Pimavanserin is classified under ATC code N05AX17 (Pimavanserin).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.